The present invention relates to an improved process for the preparation of Imatinib or Imatinib Mesylate alpha form. The present invention also disclosed the new crystalline form of Imatinib base and process for the preparation of Imatinib base or Imatinib Mesylate which is free from genotoxic impurity of formula III.